Brain stimulation reduces persistent stiffness
- Trial ID
- NCT05656586
- Official Title
- Mechanisms and Effects of Pallidal Deep Brain Stimulation on Levodopa Resistant Motor Signs in Parkinson's Disease; Udall Project 2 Aim 2A&C
- Goal
- Brain stimulation reduces persistent stiffness
- Status
- RECRUITING
- Sponsor
- University of Minnesota
- Study Type
- OBSERVATIONAL
- Enrollment
- 36 participants
- Conditions
- Parkinson Disease
- Interventions
- observational-- no intervention
Plain-Language Summary
The goal is to understand how stimulation of the globus pallidus internus helps movement problems in Parkinson's that do not respond well to levodopa, like persistent rigidity or dystonia. The team will observe people already implanted with the Medtronic Percept DBS system, recording brain signals and motor performance during lab tasks and, when the device is set to sense, during at-home monitoring to link GPi activity patterns with changes in movement. Pallidal DBS delivers controlled electrical pulses to the GPi to normalize abnormal firing patterns, which can reduce involuntary movements or stiffness, and it is used alongside levodopa rather than replacing it. Participants must have GPi DBS with a Percept device activated at least three months, be able to consent and perform the motor tasks, and are excluded for dementia, major musculoskeletal or other neurologic disorders, post-op complications that affect safety, or incompatible DBS settings for the at-home portion.
Locations
- University of Minnesota, Minneapolis, Minnesota, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying observational-- no intervention. The goal is to understand how stimulation of the globus pallidus internus helps movement problems in Parkinson's that do not respond well to levodopa, like persistent rigidity or dystonia. The team will observe people already implanted with the Medtronic Percept DBS system, recording brain signals and motor performance during lab tasks and, when the device is set to sense, during at-home monitoring to link GPi activity patterns with changes in movement. Pallidal DBS delivers controlled electrical pulses to the GPi to normalize abnormal firing patterns, which can reduce involuntary movements or stiffness, and it is used alongside levodopa rather than replacing it. Participants must have GPi DBS with a Percept device activated at least three months, be able to consent and perform the motor tasks, and are excluded for dementia, major musculoskeletal or other neurologic disorders, post-op complications that affect safety, or incompatible DBS settings for the at-home portion.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 2 months.